A Cost-Effectiveness Analysis of Amniocentesis and Chorionic Villus Sampling for Prenatal Genetic Testing
Bibliographic Data
| ID | 9102412 |
|---|---|
| Authors | Paul S Heckerling (corresponding author), Marion S Verp (University of Illinois Chicago) |
| Year | 1994 |
| Volume | 32 |
| Issue | 8 |
| Pages | 863-880 |
| Publication date | 1994-08-01 |
| Peer Reviewed | Yes |
| Open Access | No |
| Type | ARTICLE |
| Venue | Medical Care (JOURNAL) |
| Journal identifiers | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Publisher | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/00005650-199408000-00008 |
| PMID | 8057700 |
| OpenAlex | W2016961378 |
| Language | EN |
| Citations received | 1 |
| References cited | 7 |
Amniocentesis and chorionic villus sampling are tests for the prenatal diagnosis of cytogenetic abnormalities. We calculated the incremental costs per abnormal birth averted, and the incremental costs per quality-adjusted outcome, of amniocentesis and chorionic villus sampling performed for the indication of maternal age. Probabilities were obtained from the literature, and direct medical costs from hospital charges deflated to reflect aggregated contracted care reimbursements. Utilities were used to quality-adjust prenatal testing outcomes. Based on costs per abnormal birth averted, at all maternal ages from 30 to 43 years, amniocentesis was more cost-effective than chorionic villus sampling; at ages 44 and 45, chorionic villus sampling was more cost-effective. However, if the anxiety reduction provided by first-trimester diagnosis was equivalent to a 0.2% risk of an abnormal child, chorionic villus sampling was more cost-effective than amniocentesis at all maternal ages. Based on data from the 1988 United States natality cohort, the current policy of testing women aged 35 and older would cost $103,329 and $111,184 per abnormal birth averted for amniocentesis and chorionic villus sampling, respectively. Testing women aged 30 and older would almost double these costs. For either prenatal test, targeting high risk women for testing, and striving for utilization rates of 50% or higher, appeared to be the most cost-effective policy
Advanced maternal age · Amniocentesis · Biology · Chorionic villi · Chorionic villus sampling · Fetus · Gynecology · Obstetrics · Pregnancy · Prenatal diagnosis · Sampling (signal processing) · Computer Science · Genomic variations and chromosomal abnormalities · Genomics and Rare Diseases · Medicine · Prenatal Screening and Diagnostics
Utility approach to measuring health-related quality of life
Measuring the benefits of screening for open neural tube defects
Screening for spina bifida cystica. A cost-benefit analysis
Trends in utilization of prenatal cytogenetic diagnosis by New York State residents in 1979 and 1980
Maternal serum alpha-fetoprotein screening
The Selective Utilization of Prenatal Genetic Diagnosis Experiences of a Regional Program in Upstate New York During the 1970s
A benefit-cost analysis of amniocentesis
| Unique citing works | 1 |
|---|---|
| Citations per year | 0,05 |
| Citation span | 2004 - 2004 (1) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 1 |